Chrono Therapeutics and the Parkinsonís Institute and Clinical Center announced today the formation of a strategic alliance focused on collaborating on how medicine is delivered to Parkinsonís patients.
Published Monday, October 23, 2017 2:00 pm

The collaboration focuses on understanding the latest methods in delivering needed drugs to Parkinson’s patients transdermally. "This is a unique opportunity for a leading biopharmaceutical company and a world-renowned research institute to combine forces to make a significant impact on Parkinson’s,” said Dr. Carrolee Barlow, CEO Parkinson’s Institute and Clinical Center. “At the Institute, we discovered pulsatile nicotine for the treatment of levodopa induced dyskinesias and our collaboration with Chrono Therapeutics allows our patients to receive the treatment in a very timely manner.

Click here for more

Send this page to a friend

Show Other Stories

2500 Hospital Drive, Bldg #10, Suite 1 | Mountain View, CA 94040
650.770.0201 main | 650.770.0204 fax (Clinic Secure)